Abstract:Transforming growth factor-β (TGF-β) is the primary factor that drives fibrosis in most, if not all, forms of chronic kidney disease (CKD). However, direct targeting of TGF-β is unlikely to be therapeutically feasible due to the involvement of TGF-β in other systems, including the immune system. Hence, the aim of this study was to identify Sirtuin 2 (SIRT2) as an endogenous regulatory of TGF-β signaling and renal fibrosis. In current study, we demonstrated that SIRT2 was downregulated in the renal tubules of patients with CKD and DKD, as well as a mouse model of renal fibrosis. In kidneys that are obstructed, specific deletion of Sirt2 in renal tubule epithelial cells (TEC) were shown to substantially aggravate renal fibrosis, and renal tubule specific overexpression of Sirt2 was sufficient to ameliorate renal fibrosis. Additionally, we showed that SIRT2 overexpression and knockdown restrained and enhanced TGF-β-induced fibrotic gene expression, respectively, in TEC. Mechanistically, SIRT2 reduced the phosphorylation, nuclear localization, and protein levels of SMAD2, leading to inhibition of the TGF-β signaling pathway. Further studies found that SIRT2 was able to directly interact with and deacetylate SMAD2 on lysine 451 and promote its ubiquitination and degradation. The mutation of lysine 451 to arginine in SMAD2 blocks the regulatory effect of SIRT2. Notably, loss of SMAD specific E3 ubiquitin protein ligase 2 abolished the ubiquitination and degradation of SMAD2 induced by SIRT2 in SMAD2. This study provides initial indication of the anti-fibrotic role of SIRT2 in renal tubules, suggesting its therapeutic potential for renal fibrosis.Funding Information: This work was supported by grants from the National Natural Science Foundation of China (82000824 to SY, 82170842 to ZL, 82171556 to LK), the Natural Science Foundation of Shenzhen City, China to ZL (No. KCXFZ20201221173600001), the National Key Research and Development Program of China (2018YFC2001100). Declaration of Interests: The authors have declared that no conflict of interest exists.Ethics Approval Statement: This study was approved by the Institutional Review Board and Ethics Committee of the Shenzhen People’s Hospital (approval no. LL-KT-2018338). Written informed consent was obtained from all participants prior to their inclusion in the study.All Animal care and experimental protocols for in vivo studies conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH; NIH publication no.:85–23, revised 1996) and were approved by the Ethics Committee of the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital (Shenzhen, China).

SIRT2 Alleviated Renal Fibrosis by Deacetylating SMAD2 and SMAD3 in Renal Tubular Epithelial Cells.

SIRT2 Alleviated Renal Fibrosis by Deacetylating Conserved Lysine 451 on SMAD2 in Renal Tubular Epithelial Cells

Inhibition of SIRT2 Alleviates Fibroblast Activation and Renal Tubulointerstitial Fibrosis Via MDM2

Smad2 Protects Against TGF-β/Smad3-Mediated Renal Fibrosis

Upregulation of Mirna-1228-3p Alleviates TGF-β-induced Fibrosis in Renal Tubular Epithelial Cells.

Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy.

MiR-155-5p Promotes Renal Interstitial Fibrosis in Obstructive Nephropathy Via Inhibiting SIRT1 Signaling Pathway

Nuclear Translocation of SIRT4 Mediates Deacetylation of U2AF2 to Modulate Renal Fibrosis Through Alternative Splicing-mediated Upregulation of CCN2

Smad7 Inhibits Fibrotic Effect of TGF- on Renal Tubular Epithelial Cells by Blocking Smad2 Activation

Sirtuin 3 regulates mitochondrial protein acetylation and metabolism in tubular epithelial cells during renal fibrosis

Mir-192 Mediates TGF-beta/Smad3-driven Renal Fibrosis.

Inhibition of Sirt2 Alleviates Fibroblasts Activation and Pulmonary Fibrosis via Smad2/3 Pathway

Renal Fibrosis: SIRT1 Still of Value

Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis

TGF2 and TGF3 isoforms drive fibrotic disease pathogenesis

SIRT3 Prevents Angiotensin II-induced Renal Tubular Epithelial-Mesenchymal Transition by Ameliorating Oxidative Stress and Mitochondrial Dysfunction.

Activation Of Sirtuin-1 Promotes Renal Fibroblast Activation And Aggravates Renal Fibrogenesis

SIRT3 blocks aging-associated tissue fibrosis in mice by deacetylating and activating GSK3β.

Sirt6 Alleviated Liver Fibrosis by Deacetylating Conserved Lysine 54 on Smad2 in Hepatic Stellate Cells

Activation of SIRT3 by Tanshinone IIA ameliorates renal fibrosis by suppressing the TGF-β/TSP-1 pathway and attenuating oxidative stress

SIRT1 Inhibits TGF‐β‐induced Endothelial‐mesenchymal Transition in Human Endothelial Cells with Smad4 Deacetylation